NovoCure Limited (NVCR)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NovoCure Limited (“Novocure” or “the Company”) (NASDAQ: NVCR). Investors who purchased Novocure securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Novocure has violated federal securities laws.
Novocure Investigation Details
On October 30, 2025, NovoCure touted the benefits of starting Tumor Treating Fields (“TTFields”) therapy earlier in the treatment cycle. But the Company’s Phase 3 TRIDENT trial failed to find a statistically significant improvement with this approach. Following this news, Novocure’s stock price dropped 20% on June 18, 2026.
What’s Next for Novocure Investors?
If you are aware of any facts relating to this investigation or purchased Novocure securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Novocure Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For Novocure Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.